Efficacy of thalidomide therapy in pediatric Crohn’s disease with evidence of tuberculosis

Table 1 Clinical characteristics of all cases treated with thalidomide

Patient No.	Sex	Age at thalidomide treatment	Disease duration before thalidomide	Age at ATT treatment	Disease distribution	Extra-intestinal symptoms	TB status before ATT	ATT medications and duration	Thalidomide starting dose	Thalidomide final dose (duration)	Follow-up time (mo)	Response
1	M	2 yr 8 mo	26 mo	1 yr 3 mo	Ileocolonic	Joint lesions	AFB (+), PPD (+)	HRZ, 6 m;	2.5 mg/kg per day	- (34 m)	38 mo	Remission
								HRZEP, 6 mo
2	F	2 yr	23 mo	2 mo	Colon	Perianal abscess	AFB (+)	HRZ, 3 mo;	2.5 mg/kg per day	- (7 m)	10 mo	No response
								HR, 15 mo
3	F	2 yr 4 mo	28 mo	7 mo	Colon	Perianal abscess	AFB (+)	HRZ, 9 mo;	2 mg/kg per day	0.33 mg/kg per day	33 mo	Response
								HREP, 27 mo
4	F	11 yr 7 mo	42 mo	8 yr 1 mo	Ileocolonic	Perianal skin tag	AFB (+)	HREZ, 12 mo	1.8 mg/kg per day	0.8 mg/kg per day	15 mo	Response
5	M	12 yr 6 mo	18 mo	11 yr 3 mo	Ileocolonic	Oral ulcers	TB culture (+),	HRS, 5 mo;	2 mg/kg per day	0.5 mg/kg per day	36 mo	Remission
							Spleen TB	HRE, 12 mo
6	M	12 yr 5 mo	20 mo	11 yr 5 mo	Ileocolonic	Anal fistula	AFB (+)	HRZ, 12 mo	1.2 mg/kg per day	0.6 mg/kg per day	12 mo	Remission
7	M	8 yr 6 mo	38 mo	5 yr 4 mo	Ileal	Pleural and ascetic fluid	PPD (+)	HRE, 3 mo;	2 mg/kg per day	- (44 m)	44 mo	Remission
								HRZ, 12 mo
8	F	3 yr 8 mo	16 mo	2 yr 4 mo	Ileocolonic	-	AFB (+)	HRZ, 14 mo;	2 mg/kg per day	1.6 mg/kg per day	16 mo	Response
								HRE, 12 mo
9	F	2 yr 4 mo	16 mo	1 yr	Ileocolonic	Anal fissure	AFB (+)	HRZ, 14 mo	2.2 mg/kg per day	1.8 mg/kg per day	9 mo	Remission
10	F	13 yr 6 mo	17 mo	12 yr 1 mo	Ileocolonic	Perianal skin tag	AFB (+)	HREZ, 3 mo;	1.8 mg/kg per day	1.3 mg/kg per day	9 mo	Remission
								HR, 15 mo

ATT: Anti-tubercular treatment; H: Isoniazid; R: Rifampicin; Z: Pyrazinamide; E: Ethambutol; S: Streptomycin; P: Para-aminosalicylic acid.